Radioimmunoimaging with longer-lived positron-emitting radionuclides: Potentials and challenges

Bioconjugate Chemistry

Volumn 20, Issue 5, 2009, Pages 825-841

  Nayak, Tapan K ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DOSIMETRY; ELECTRONS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; POSITRONS; RADIOISOTOPES; SURFACE PLASMON RESONANCE;

AREA OF INTEREST; CLINICAL TRANSLATION; HALF LIVES; IMAGING CHARACTERISTICS; IMAGING TECHNOLOGY; POSITRON EMITTERS; RADIOIMMUNOIMAGING; RADIOLABELLING;

MONOCLONAL ANTIBODIES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CU 64 PLUS CETUXIMAB; 2 AMINO 3 [(4 ISOTHIOCYANATOPHENYL)PROPYL]TRANSCYCLOHEXANE 1,2 DIAMINE PENTAACETIC ACID PLUS TRASTUZUMAB; ARSENIC 72; BEVACIZUMAB; BROMINE 76; CARBON 11; CETUXIMAB; COBALT 55; COPPER 64; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IODINE 123; IODINE 124; IODINE 125; IODINE 131; IRON 55; MANGANESE 52; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H17E2; OXYGEN 18; PENTETATE YTTERBIUM YB 90; PENTETIC ACID GA 66; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TRASTUZUMAB; TRIENTINE 1 A3 PLUS CU 64; UNCLASSIFIED DRUG; YTTRIUM 86; RADIOISOTOPE;

ANTIBODY ENGINEERING; ANTIBODY LABELING; ANTIGEN BINDING; BRAIN DAMAGE; BROMINATION; CANCER SIZE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG CONJUGATION; HALF LIFE TIME; HEART MUSCLE NECROSIS; HUMAN; IODINATION; ISOTOPE LABELING; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MEDICINE; OCCULT CANCER; OXIDATION REDUCTION REACTION; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION INJURY; RADIODIAGNOSIS; RADIOIMMUNOLOGY; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOCHEMISTRY; STROKE; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING; ANIMAL; DIAGNOSTIC USE; ELECTRON; RADIOIMMUNOASSAY; SUPPLY AND DISTRIBUTION;

ANIMALS; ELECTRONS; HALF-LIFE; HUMANS; RADIOIMMUNODETECTION; RADIOISOTOPES;

EID: 66149192414     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800299f     Document Type: Review

References (183)

1. Cattell, H. W. (1896) Application of the X-rays to surgery. Science 3, 344-346.
2. Wagner, H. N., Jr., and Bardfeld, P. A. (1967) Evaluation of structure and function of spleen with radioactive tracers. JAMA 199, 202-206
3. Wagner, H. N., Jr. (1963) The current status of nuclear medicine. JAMA 183, 500-503
4. Boswell, C. A., and Brechbiel, M. W. (2007) Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl. Med. Biol. 34, 757-778 (Pubitemid 47503817)
5. Khaw, B. A. (2005) Antibodies for molecular imaging in the cardiovascular system. J. Nucl. Cardiol. 12, 591-604. (Pubitemid 41364062)
6. Melcher, L. R., and Masouredis, S. P. (1951) The in vivo stability of the I131 protein label of rabbit antibody in guinea pigs as determined by the quantitative precipitin reaction. J. Immunol. 67, 393-402.
7. Pressman, D. (1949) The zone of localization of antibodies; the specific localization of antibodies to rat kidney. Cancer 2, 697-700.
8. McCardle, R. J., Harper, P. V., Spar, I. L., Bale, W. F., Andros, G., and Jiminez, F. (1966) Studies with iodine-131-labeled antibody to human fibrinogen for diagnosis and therapy of tumors. J. Nucl. Med. 7, 837-847
9. Goldenberg, D. M., DeLand, F., Kim, E., Bennett, S., Primus, F. J., van Nagell, J. R., Jr., Estes, N., DeSimone, P., and Rayburn, P. (1978) Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med. 298, 1384-1386 (Pubitemid 8358628)
10. Kohler, G., and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497
11. Goldenberg, D. M., Kim, E. E., Deland, F., Spremulli, E., Nelson, M. O., Gockerman, J. P., Primus, F. J., Corgan, R. L., and Alpert, E. (1980) Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein. Cancer 45, 2500-2505 (Pubitemid 10105301)
12. O'Donnell, R. T., DeNardo, S. J., Yuan, A., Shen, S., Richman, C. M., Lara, P. N., Griffith, I. J., Goldstein, D. S., Kukis, D. L., Martinez, G. S., Mirick, G. R., DeNardo, G. L., and Meyers, F. J. (2001) Radioimmunotherapy with (111)In/ (90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. 7, 1561-1568 (Pubitemid 32708620)
13. 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 533-541
14. Mach, J. P., Carrel, S., Forni, M., Ritschard, J., Donath, A., and Alberto, P. (1980) Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N. Engl. J. Med. 303, 5-10. (Pubitemid 10073390)
15. Phelps, M. E. (2000) PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41, 661-681 (Pubitemid 30207744)
16. Otsuka, F. L., Welch, M. J., Kilbourn, M. R., Dence, C. S., Dilley, W. G., and Wells, S. A., Jr. (1991) Antibody fragments labeled with fluorine-18 and gallium-68: in vivo comparison with indium-111 and iodine-125-labeled fragments. Int. J. Rad. Appl. Instrum. B 18, 813-816
17. Garg, P. K., Garg, S., Bigner, D. D., and Zalutsky, M. R. (1992) Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. Cancer Res. 52, 5054-5060
18. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 48, 304-310
19. Kramer-Marek, G., Kiesewetter, D. O., Martiniova, L., Jagoda, E., Lee, S. B., and Capala, J. (2008) [(18)F]FBEM-Z(HER2: 342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 35, 1008-1018
20. Vaidyanathan, G., Bigner, D. D., and Zalutsky, M. R. (1992) Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. J. Nucl. Med. 33, 1535-1541
21. 124I-labelled monoclonal antibody H17E2 in a human tumour xenograft model. A prelude to positron emission tomography (PET). Br. J. Cancer Suppl. 10, 89-91.
22. Pentlow, K. S., Graham, M. C., Lambrecht, R. M., Cheung, N. K., and Larson, S. M. (1991) Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med. Phys. 18, 357-366
23. Bakir, M. A., Eccles, S., Babich, J. W., Aftab, N., Styles, J., Dean, C. J., Lambrecht, R. M., and Ott, R. J. (1992) c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J. Nucl. Med. 33, 2154-2160
24. 124I. Appl. Radiat. Isot. 55, 149-156
25. 124I reaction. Appl. Radiat. Isot. 64, 965-970
26. Tang, L. (2007) Radionuclide production and yields at Washington University School of Medicine. Q. J. Nucl. Med. Mol. Imaging 52, 122-133
27. 124I reactions and the effect of target enrichment on radionuclidic purity. Int. J. Appl. Radiat. Isot. 28, 395-401.
28. Pressman, D., Hill, R. F., and Foote, F. W. (1949) The zone of localization of anti-mouse-kidney serum as determined by radioautographs. Science 109, 65-66.
29. Yalow, R. S., and Berson, S. A. (1959) Assay of plasma insulin in human subjects by immunological methods. Nature 184, 1648-1649
30. Hunter, W. M., and Greenwood, F. C. (1962) Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194, 495-496
31. Greenwood, F. C., Hunter, W. M., and Glover, J. S. (1963) The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem. J. 89, 114-123
32. Marchalonis, J. J. (1969) An enzymic method for the trace iodination of immunoglobulins and other proteins. Biochem. J. 113, 299-305.
33. David, G. S. (1972) Solid state lactoperoxidase: a highly stable enzyme for simple, gentle iodination of proteins. Biochem. Biophys. Res. Commun. 48, 464-471
34. Rudinger, J., and Ruegg, U. (1973) Appendix: Preparation of N-succinimidyl 3-(4-hydroxyphenyl)propionate. Biochem. J. 133, 538-539.
35. 125I-containing acylating agent. Biochem. J. 133, 529-539
36. Salacinski, P. R., McLean, C., Sykes, J. E., Clement-Jones, V. V., and Lowry, P. J. (1981) Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril (Iodogen). Anal. Biochem. 117, 136-146 (Pubitemid 12211794)
37. Wilbur, D. S., Hadley, S. W., Hylarides, M. D., Abrams, P. G., Beaumier, P. A., Morgan, A. C., Reno, J. M., and Fritzberg, A. R. (1989) Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med. 30, 216-226 (Pubitemid 19048517)
38. Press, O. W., DeSantes, K., Anderson, S. K., and Geissler, F. (1990) Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. Cancer Res. 50, 1243-1250 (Pubitemid 20084019)
39. Geissler, F., Anderson, S. K., and Press, O. (1991) Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol. 137, 96-110.
40. Geissler, F., Anderson, S. K., Venkatesan, P., and Press, O. (1992) Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 52, 2907-2915
41. Sharkey, R. M., Behr, T. M., Mattes, M. J., Stein, R., Griffiths, G. L., Shih, L. B., Hansen, H. J., Blumenthal, R. D., Dunn, R. M., Juweid, M. E., and Goldenberg, D. M. (1997) Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol. Immunother. 44, 179-188 (Pubitemid 27278391)
42. Mattes, M. J., Shih, L. B., Govindan, S. V., Sharkey, R. M., Ong, G. L., Xuan, H., and Goldenberg, D. M. (1997) The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int. J. Cancer 71, 429-435 (Pubitemid 27224309)
43. Stein, R., Goldenberg, D. M., Thorpe, S. R., Basu, A., and Mattes, M. J. (1995) Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res. 55, 3132-3139
44. Stein, R., Govindan, S. V., Mattes, M. J., Chen, S., Reed, L., Newsome, G., McBride, B. J., Griffiths, G. L., Hansen, H. J., and Goldenberg, D. M. (2003) Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res. 63, 111-118 (Pubitemid 36070428)
45. Wilbur, D. S. (1992) Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjugate Chem. 3, 433-470
46. 124)I] iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 62, 5912-5919
47. Sundaresan, G., Yazaki, P. J., Shively, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F., Gambhir, S. S., and Wu, A. M. (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44, 1962-1969 (Pubitemid 40022142)
48. Fortin, M. A., Salnikov, A. V., Nestor, M., Heldin, N. E., Rubin, K., and Lundqvist, H. (2007) Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur. J. Nucl. Med. Mol. Imaging 34, 1376-1387 (Pubitemid 47312573)
49. Phan, H. T., Jager, P. L., Paans, A. M., Plukker, J. T., Sturkenboom, M. G., Sluiter, W. J., Wolffenbuttel, B. H., Dierckx, R. A., and Links, T. P. (2008) The diagnostic value of (124)I-PET in patients with differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging.
50. Freudenberg, L. S., Antoch, G., Frilling, A., Jentzen, W., Rosenbaum, S. J., Kuhl, H., Bockisch, A., and Gorges, R. (2008) Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of (124)I-PET/CT and FDG-PET. Eur. J. Nucl. Med. Mol. Imaging.
51. 124I PET and 3-dimensional internal dosimetry software. J. Nucl. Med. 48, 143-149
52. Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., Bailey, J., Smith, N., Hastings, D., Lawrance, J., Haroon, H., Ward, T., McGown, A. T., Tang, M., Levitt, D., Marreaud, S., Lehmann, F. F., Herold, M., and Zwierzina, H. (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. 94, 1484-1493 (Pubitemid 35251753)
53. 124I- cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 8, 304-310
54. Vedeneyev, V. I. G., L. V.; Kondrat'YevV. N.; Medvedev, V. A. (1966) Bond energies, ionization potentials and electron affinities, Edward Arnold, London.
55. Orlova, A., Hoglund, J., Lubberink, M., Lebeda, O., Gedda, L., Lundqvist, H., Tolmachev, V., and Sundin, A. (2002) Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. Cancer Biother. Radiopharm. 17, 385-396
56. Rossin, R., Berndorff, D., Friebe, M., Dinkelborg, L. M., and Welch, M. J. (2007) Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. J. Nucl. Med. 48, 1172-1179 (Pubitemid 47052658)
57. Bergstrom, M., Lu, L., Fasth, K. J., Wu, F., Bergstrom-Pettermann, E., Tolmachev, V., Hedberg, E., Cheng, A., and Langstrom, B. (1998) In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J. Nucl. Med. 39, 1273-1279 (Pubitemid 28326167)
58. 76Br]MBBG). Nucl. Med. Biol. 21, 49-55.
59. 76Br and its use in labeling proteins. Acta Radiol. Suppl. 376, 64.
60. 125I by direct or indirect synthetic methods. J. Nucl. Med. 18, 282-288
61. 77Br]bromobenzoate. Int. J. Rad. Appl. Instrum. B 18, 363-365
62. 76Br-labeled monoclonal anti-CEA antibodies for radioimmuno positron emission tomography. Nucl. Med. Biol. 22, 125-131
63. 76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl. Med. Biol. 31, 425-433
64. Mume, E., Orlova, A., Larsson, B., Nilsson, A. S., Nilsson, F. Y., Sjoberg, S., and Tolmachev, V. (2005) Evaluation of ((4-hydroxyphenyl)ethyl) maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem. 16, 1547-1555 (Pubitemid 41683137)
65. Lovqvist, A., Sundin, A., Ahlstrom, H., Carlsson, J., and Lundqvist, H. (1997) Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J. Nucl. Med. 38, 395-401. (Pubitemid 27376892)
66. 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties. Med. Phys. 26, 249-258
67. Lovqvist, A., Sundin, A., Roberto, A., Ahlstrom, H., Carlsson, J., and Lundqvist, H. (1997) Comparative PET imaging of experimental tumors with bromine-76-labeled antibodies, fluorine-18-fluorodeoxyglucose and carbon-11-methionine. J. Nucl. Med. 38, 1029-1035 (Pubitemid 27339606)
68. 76Br]bromobenzoate for radioimmuno PET. Nucl. Med. Biol. 27, 837-843
69. 76Br]bromospiperone. Eur. J. Pharmacol. 114, 267-272
70. 76Br]bromospiperone in untreated schizophrenic patients. Am. J. Psychiatry 147, 44-50.
71. Davidsson, L., Cederblad, A., Hagebo, E., Lonnerdal, B., and Sandstrom, B. (1988) Intrinsic and extrinsic labeling for studies of manganese absorption in humans. J. Nutr. 118, 1517-1521 (Pubitemid 19042208)
72. 3He-activation of vanadium. Int. J. Appl. Radiat. Isotopes 32, 246-247.
73. 77Kr for positron emission tomography. J. Labelled Compd. Radiopharm. 16, 129-130.
74. 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur. J. Nucl. Med. Mol. Imaging 1-7.
75. Cikrt, M. (1972) Biliary excretion of 203 Hg, 64 Cu, 52 Mn, and 210 Pb in the rat. Br. J. Ind. Med. 29, 74-80.
76. Sharma, H, Z. J., Smith, A. M., and Downey, S. (1986) Production of cobalt-55, a short-lived, positron emitting radio-label for bleomycin. Int. J. Radiat. Instrum. [A] 37, 105-109. (Pubitemid 16639733)
77. Srivastava, S. C., M, L. F., Kolsky, K. L., Mease, R. C., Joshi, V., Meinken, G. E., Pyatt, B., Wolf, A. P., Schlyder, D. J., Levy, A. V., and Fowler, J. S. (1994) Production and use of cobalt-55 as an antibody label for PET imaging. J. Labelled Compd. Radiopharm. 35, 389-391. (Pubitemid 24159394)
78. Lagunas-Solar, M. C., and Jungerman, J. A. (1979) Cyclotron production of carrier-free cobalt-55, a new positron-emitting label for bleomycin. Int. J. Appl. Radiat. Isot. 30, 25-32. (Pubitemid 9115348)
79. Goethals, P., Volkaert, A., Vandewielle, C., Dierckx, R., and Lameire, N. (2000) 55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. Nucl. Med. Biol. 27, 77-81. (Pubitemid 30099618)
80. 55Co-bleomycin single photon scintigraphy. Eur. J. Nucl. Med. 7, 104-107
81. Stevens, H., Jansen, H. M., De Reuck, J., Lemmerling, M., Strijckmans, K., Goethals, P., Lemahieu, I., de Jong, B. M., Willemsen, A. T., and Korf, J. (1999) 55Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI. J. Neurol. Sci. 171, 11-18 (Pubitemid 29525572)
82. Jansen, H. M., Paans, A. M., vd Vliet, A. M., Veenma-van der Duin, L., Bolwijn-Meijer, C. J., Pruim, J., Willemsen, A. T., Franssen, E. J., Minderhoud, J. M., and Korf, J. (1997) Cobalt-55 positron emission tomography in ischemic stroke. Clin. Neurol. Neurosurg. 99, 6-10.
83. Byegård, J, S. G., and Skålberg, M. (1999) The stability of some metal EDTA, DTPA and DOTA complexes: Application as tracers in groundwater studies. J. Radioanal. Nucl. Chem. 241, 281-290. (Pubitemid 29387494)
84. Heppeler, A., Andre, J. P., Buschmann, I., Wang, X., Reubi, J. C., Hennig, M., Kaden, T. A., and Maecke, H. R. (2008) Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chemistry 14, 3026-3034
85. Kukis, D. L., DeNardo, S. J., DeNardo, G. L., O'Donnell, R. T., and Meares, C. F. (1998) Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J. Nucl. Med. 39, 2105-2110 (Pubitemid 29001799)
86. Kukis, D. L., DeNardo, G. L., DeNardo, S. J., Mirick, G. R., Miers, L. A., Greiner, D. P., and Meares, C. F. (1995) Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res. 55, 878-884
87. Beekhuis, H., and Nieweg, O. E. (1984) Radiation absorbed doses from Co-57- and Co-55 bleomycin. J. Nucl. Med. 25, 478-485 (Pubitemid 14131974)
88. Bowen, H. (1966) The Biogeochemistry of the Elements, in Trace Elements in Biochemistry, pp 173-239, Academic Press, London.
89. 66Ga and labeling of antimyosin antibody for positron imaging of acute myocardial infarction. Eur. J. Nucl. Med. 16, 237-240
90. 66Ga as an isotope for PET imaging and quantification. Med. Phys. 24, 317-326
91. 67Ga at a compact cyclotron. Acta Radiol. Suppl. 376, 62-63
92. 66Ga as a positron emitting label of albumin colloids for clinical use. Eur. J. Nucl. Med. 14, 152-154
93. Zweit, J., Sharma, H., and Downey, S. (1987) Production of gallium-66, a short-lived, positron emitting radionuclide. Int. J. Rad. Appl. Instrum. [A] 38, 499-501. (Pubitemid 17107760)
94. Green, M. A., and Welch, M. J. (1989) Gallium radiopharmaceutical chemistry. Int. J. Rad. Appl. Instrum. B 16, 435-448 (Pubitemid 19213884)
95. Brechbiel, M. W. (2008) Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 52, 166-173
96. 2+ binding to serum transferrin. J. Inorg. Biochem. 54, 1-19.
97. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjugate Chem. 13, 530-541
98. 67Ga-labeled antibody via 1B4M or C-NOTA chelates. Nucl. Med. Biol. 24, 225-230
99. 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjugate Chem. 19, 569-573
100. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl. Med. Biol. 30, 725-731
101. Ugur, O., Kothari, P. J., Finn, R. D., Zanzonico, P., Ruan, S., Guenther, I., Maecke, H. R., and Larson, S. M. (2002) Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl. Med. Biol. 29, 147-157 (Pubitemid 34127947)
102. Van Der Werff, J. T. (1954) Clinical investigations on the use of radioactive gallium (Ga66 and Ga67) in bone diseases. Acta Radiol. 41, 343-347
103. 68Ga-DOTA-D-Phe1-Tyr3- octreotide kinetics in patients with meningiomas. J. Nucl. Med. 46, 763-769
104. 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 1115-1122
105. 18F-FDG PET. J. Nucl. Med. 47, 793-796
106. Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., and Larson, S. M. (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. 22, 701-706 (Pubitemid 38702826)
107. Jennewein, M., Qaim, S. M., Hermanne, A., Jahn, M., Tsyganov, E., Slavine, N., Seliounine, S., Antich, P. A., Kulkarni, P. V., Thorpe, P. E., Mason, R. P., and Rösch, F. (2005) A new method for radiochemical separation of arsenic from irradiated germanium oxide. Appl. Radiat. Isot. 63, 343-351. (Pubitemid 40961712)
108. 72As radionuclide generator based on solid phase extraction. Radiochim. Acta 93, 579-583.
109. 72As radionuclide generator based on distillation. Radiochim. Acta 92, 245-249.
110. 72As. Int. J. Appl. Radiat. Isot. 29, 607-609.
111. Jennewein, M., Lewis, M. A., Zhao, D., Tsyganov, E., Slavine, N., He, J., Watkins, L., Kodibagkar, V. D., O'Kelly, S., Kulkarni, P., Antich, P. P., Hermanne, A., Rosch, F., Mason, R. P., and Thorpe, P. E. (2008) Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin. Cancer Res. 14, 1377-1385
112. Turner, P. C. (1962) The calculation of absorbed tissue doses from arsenic-72. Phys. Med. Biol. 7, 329-334
113. 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model. Clin. Cancer Res. 5, 3207s-3212s.
114. Ruangma, A., Bai, B., Lewis, J. S., Sun, X., Welch, M. J., Leahy, R., and Laforest, R. (2006) Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides. Nucl. Med. Biol. 33, 217-226
115. Obata, A., Kasamatsu, S., McCarthy, D. W., Welch, M. J., Saji, H., Yonekura, Y., and Fujibayashi, Y. (2003) Production of therapeutic quantities of (64)Cu using a 12 MeV cyclotron. Nucl. Med. Biol. 30, 535-539 (Pubitemid 36776524)
116. 64Cu using a biomedical cyclotron. Nucl. Med. Biol. 24, 35-43.
117. 64Cu from zinc metal irradiated under boron shielding. Cancer 73, 774-778
118. 67Cu process. Appl. Radiat. Isot. 59, 343-351
119. Qaim, S. M. (2008) Decay data and production yields of some non-standard positron emitters used in PET. Q. J. Nucl. Med. Mol. Imaging 52, 111-116
120. 64Cu. Nucl. Instrum. Methods Phys. Res., Sect. B 240, 625-637.
121. 57Co. Int. J. Rad. Appl. Instrum. B 13, 363-368
122. 64Cu using a conjugate containing a macrocyclic amine chelating agent. Int. J. Radiat. Appl. Instrum., Part B 14, 479-484.
123. Rogers, B. E., Anderson, C. J., Connett, J. M., Guo, L. W., Edwards, W. B., Sherman, E. L., Zinn, K. R., and Welch, M. J. (1996) Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjugate Chem. 7, 511-522 (Pubitemid 26312142)
124. Anderson, C. J., Connett, J. M., Schwarz, S. W., Rocque, P. A., Guo, L. W., Philpott, G. W., Zinn, K. R., Meares, C. F., and Welch, M. J. (1992) Copper-64-labeled antibodies for PET imaging. J. Nucl. Med. 33, 1685-1691
125. 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother. Radiopharm. 23, 158-171
126. Anderson, C. J., Wadas, T. J., Wong, E. H., and Weisman, G. R. (2008) Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q. J. Nucl. Med. Mol. Imaging 52, 185-192
127. Sprague, J. E., Peng, Y., Sun, X., Weisman, G. R., Wong, E. H., Achilefu, S., and Anderson, C. J. (2004) Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin. Cancer Res. 10, 8674-8682 (Pubitemid 40053436)
128. 64Cu-SarAr immunoconjugates. Proc. Natl. Acad. Sci. U.S.A. 104, 17489-17493
129. Bhalgat, M. K., Roberts, J. C., Mercer-Smith, J. A., Knotts, B. D., Vessella, R. L., and Lavallee, D. K. (1997) Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin- A6H immunoconjugates. Nucl. Med. Biol. 24, 179-185 (Pubitemid 27146121)
130. Ping Li, W., Meyer, L. A., Capretto, D. A., Sherman, C. D., and Anderson, C. J. (2008) Receptor-binding, biodistribution, and metabolism studies of (64)Cu-DOTA-Cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother. Radiopharm. 23, 158-171
131. 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 66, 9673-9681
132. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur. J. Nucl. Med. Mol. Imaging 34, 850-858
133. 64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin. Cancer Res. 11, 5112-5120
134. 64Cu-labelled anti-L1-CAM antibody chCE7. Eur. J. Nucl. Med. Mol. Imaging 30, 1066.
135. Li, L., Bading, J., Yazaki, P. J., Ahuja, A. H., Crow, D., Colcher, D., Williams, L. E., Wong, J. Y., Raubitschek, A., and Shively, J. E. (2008) A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody
136. 67Cu. Proc. Natl. Acad. Sci. U.S.A. 93, 6814-6818
137. Philpott, G. W., Schwarz, S. W., Anderson, C. J., Dehdashti, F., Connett, J. M., Zinn, K. R., Meares, C. F., Cutler, P. D., Welch, M. J., and Siegel, B. A. (1995) RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med. 36, 1818-1824
138. Yoo, J., Tang, L., Perkins, T. A., Rowland, D. J., Laforest, R., Lewis, J. S., and Welch, M. J. (2005) Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl. Med. Biol. 32, 891-897 (Pubitemid 41505323)
139. 111In labeled Herceptin. Nucl. Med. Biol. 29, 599-606.
140. 86Y purification using a three-column system. Nucl. Med. Biol. 31, 297-301.
141. Smith, S., Thomas, R. M., Steere, H. A., Beatty, H. E., Dawson, K. B., and Peckham, M. J. (1976) Therapeutic irradiation of the central nervous system using intrathecal 90Y-DTA. Br. J. Radiol. 49, 141-147
142. Hnatowich, D. J., Virzi, F., and Doherty, P. W. (1985) DTPA-coupled antibodies labeled with yttrium-90. J. Nucl. Med. 26, 503-509 (Pubitemid 16192246)
143. Sharkey, R. M., Motta-Hennessy, C., Gansow, O. A., Brechbiel, M. W., Fand, I., Griffiths, G. L., Jones, A. L., and Goldenberg, D. M. (1990) Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Int. J. Cancer 46, 79-85. (Pubitemid 20225791)
144. 90Y-labeled monoclonal antibody CO17-1A. Int. J. Rad. Appl. Instrum. B 18, 313-321
145. 90Y radioimmunotherapy. Bioconjugate Chem. 2, 187-194
146. Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., et al. (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med. 35, 882-889 (Pubitemid 24151230)
147. 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts. Nucl. Med. Biol. 20, 955-962
148. Kobayashi, H., Wu, C., Yoo, T. M., Sun, B. F., Drumm, D., Pastan, I., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., and Brechbiel, M. W. (1998) Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J. Nucl. Med. 39, 829-836 (Pubitemid 28216733)
149. Deshpande, S. V., DeNardo, S. J., Kukis, D. L., Moi, M. K., McCall, M. J., DeNardo, G. L., and Meares, C. F. (1990) Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med. 31, 473-479 (Pubitemid 20144715)
150. 90Y from cyclic and acyclic ligand-antibody conjugates. Int. J. Rad. Appl. Instrum. B 18, 469-476
151. Wong, J. Y., Chu, D. Z., Williams, L. E., Liu, A., Zhan, J., Yamauchi, D. M., Wilczynski, S., Wu, A. M., Yazaki, P. J., Shively, J. E., Leong, L., and Raubitschek, A. A. (2006) A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother. Radiopharm. 21, 88-100. (Pubitemid 43830430)
152. Palm, S., Enmon, R. M., Jr., Matei, C., Kolbert, K. S., Xu, S., Zanzonico, P. B., Finn, R. L., Koutcher, J. A., Larson, S. M., and Sgouros, G. (2003) Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J. Nucl. Med. 44, 1148-1155 (Pubitemid 39663389)
153. Lovqvist, A., Humm, J. L., Sheikh, A., Finn, R. D., Koziorowski, J., Ruan, S., Pentlow, K. S., Jungbluth, A., Welt, S., Lee, F. T., Brechbiel, M. W., and Larson, S. M. (2001) PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. J. Nucl. Med. 42, 1281-1287 (Pubitemid 32717850)
154. Regino, C. M. D., Wong, K. , Garmestani, K. , Baidoo, K., Williams, M. , Seidel, J. , Green, M. , Choyke, P. , and Brechbiel, M. (2008) Abstract #3159 in 99th Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research, San Diego.
155. 86Y-DOTA0)-D- Phe1-Tyr3-octreotide(SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging 30, 510-518
156. Perk, L. R., Visser, G. W., Vosjan, M. J., Stigter-van Walsum, M., Tijink, B. M., Leemans, C. R., and van Dongen, G. A. (2005) (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med. 46, 1898-1906 (Pubitemid 46196653)
157. Hohn, A., Zimmermann, K., Schaub, E., Hirzel, W., Schubiger, P. A., and Schibli, R. (2008) Production and separation of "non-standard" positron emission tomography nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute Switzerland. Q. J. Nucl. Med. Mol. Imaging.
158. Meijs, W. E., Herscheid, J. D., Haisma, H. J., and Pinedo, H. M. (1992) Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int. J. Rad. Appl. Instrum. [A] 43, 1443-1447
159. Pagani, M., Stone-Elander, S., and Larsson, S. A. (1997) Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur. J. Nucl. Med. 24, 1301-1327 (Pubitemid 27477625)
160. Link, J. M., Krohn, K. A., and Eary, J. F. (1986) 89Zr for antibody labeling and positron emission tomography. J. Labelled Compd. Radiopharm. 23, 1297-1298. (Pubitemid 17209907)
161. 89Zr-porphyrin for positron label of monoclonal antibodies. J. Labelled Compd. Radiopharm. 30, 326.
162. Meijs, W. E., Haisma, H. J., Klok, R. P., van Gog, F. B., Kievit, E., Pinedo, H. M., and Herscheid, J. D. (1997) Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J. Nucl. Med. 38, 112-118 (Pubitemid 27027011)
163. Meijs, W. E., Haisma, H. J., Van der Schors, R., Wijbrandts, R., Van den Oever, K., Klok, R. P., Pinedo, H. M., and Herscheid, J. D. (1996) A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol. 23, 439-448 (Pubitemid 26233214)
164. 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 44, 1271-1281
165. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., and White, C. A. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463 (Pubitemid 34525730)
166. Verel, I., Visser, G. W., and van Dongen, G. A. (2005) The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med. 46, 164S-71S. (Pubitemid 47619032)
167. Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., and Lub-de Hooge, M. N. (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48, 1313-1319
168. Perk, L. R., Visser, O. J., Stigter-van Walsum, M., Vosjan, M. J., Visser, G. W., Zijlstra, J. M., Huijgens, P. C., and van Dongen, G. A. (2006) Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33, 1337-1345 (Pubitemid 44630790)
169. Borjesson, P. K., Jauw, Y. W., Boellaard, R., de Bree, R., Comans, E. F., Roos, J. C., Castelijns, J. A., Vosjan, M. J., Kummer, J. A., Leemans, C. R., Lammertsma, A. A., and van Dongen, G. A. (2006) Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res. 12, 2133-2140
170. Perk, L. R., Stigter-van Walsum, M., Visser, G. W., Kloet, R. W., Vosjan, M. J., Leemans, C. R., Giaccone, G., Albano, R., Comoglio, P. M., and van Dongen, G. A. (2008) Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur. J. Nucl. Med. Mol. Imaging.
171. Laforest, R., and Liu, X. (2007) Image quality with nonstandard nuclides in positron emission tomography. Q. J. Nucl. Med. Mol. Imaging.
172. Beattie, B. J., Finn, R. D., Rowland, D. J., and Pentlow, K. S. (2003) Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade γ rays. Med. Phys. 30, 2410-2423 (Pubitemid 37129747)
173. Vandenberghe, S. (2006) Three-dimensional positron emission tomography imaging with 124I and 86Y. Nucl. Med. Commun. 27, 237-245 (Pubitemid 44391811)
174. Bale, W. F., and Spar, I. L. (1957) Studies directed toward the use of antibodies as carriers of radioactivity for therapy. Adv. Biol. Med. Phys. 5, 285-356.
175. Bale, W. F., Spar, I. L., and Goodland, R. L. (1960) Experimental radiation therapy of tumors with I-131-carrying antibodies to fibrin. Cancer Res. 20, 1488-1494
176. Milenic, D. E., Brady, E. D., and Brechbiel, M. W. (2004) Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discovery 3, 488-499
177. O'Donoghue, J. A. (1999) Implications of nonuniform tumor doses for radioimmunotherapy. J. Nucl. Med. 40, 1337-1341 (Pubitemid 29385643)
178. Howell, R. W., Goddu, S. M., and Rao, D. V. (1994) Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides. J. Nucl. Med. 35, 1861-1869 (Pubitemid 24346813)
179. Fowler, J. F. (1990) Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 18, 1261-1269 (Pubitemid 20182364)
180. Nunn, A. D. (2007) Molecular imaging and personalized medicine: an uncertain future. Cancer Biother. Radiopharm. 22, 722-739
181. Brouwers, A. H., Dorr, U., Lang, O., Boerman, O. C., Oyen, W. J., Steffens, M. G., Oosterwijk, E., Mergenthaler, H. G., Bihl, H., and Corstens, F. H. (2002) 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl. Med. Commun. 23, 229-236 (Pubitemid 34538913)
182. Rahmim, A., and Zaidi, H. (2008) PET versus SPECT: strengths, limitations and challenges. Nucl. Med. Commun. 29, 193-207.
183. Beekman, F., and van der Have, F. (2007) The pinhole: gateway to ultra-high-resolution three-dimensional radionuclide imaging. Eur. J. Nucl. Med. Mol. Imaging 34, 151-161 (Pubitemid 46147496)